TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00523965
Drug: Liposomal Amphotericin B and Paromomycin Sulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmBisome 5mg/kg iv infusion over 2 h x 1 day (single dose) + paromomycin sulfate 15 mg/kg/day i.m for 10 days, on day 2-11
Study: NCT00523965
Drug: miltefosine + Paromomycin sulfate
Normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral miltefosine 50mg once daily (\< 25 kg body weight) or twice daily ( \> 25 kg body weight) or 2.5 mg/kg for children under 12 years, for 10 days + Paromomycin sulfate 15 mg/kg/day im. for 10 days
Study: NCT00818129
Drug: AZD7295
Approvals — FDA: no, EMA: no, PMDA: no
Description: ascending single doses (start dose 90 mg), oral solution and then multiple ascending dose (tbd based on single dose results), oral solution
Study: NCT00818129
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple ascending dose (tbd based on single dose results), oral solution
Study: NCT02584400
Drug: Injection with the hypoxia tracer [18F]HX4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: The \[18F\]HX4 PET scan will be performed, by administrating 444 MBq (12 mCi) \[18F\]HX4 via a bolus IV injection.
Study: NCT01302613
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine will be delivered concurrently with the radiation therapy, at a dose of 1650 mg/m2 divided in even BID doses. It will only be taken on the days of radiation treatment (Monday-Friday, except for holidays). The A.M. dose of the capecitabine must be taken at least one hour prior to the radiation treatment.
Study: NCT01302613
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin 400 mg/m2, IV, over 2 hours before 5-FU on day 1 of each cycle. A cycle is delivered every two weeks. Three cycles will be given prior to the surgery. Five additional cycles will be given after surgery.
Study: NCT01666197
Drug: diclofenac potassium 25 mg tablet
Normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: diclofenac potassium 25 mg tablet
Study: NCT01666197
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02593682
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02512926
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01383135
Drug: F18-FPPRGD2
Normalized name: fluorodeoxyglucose F18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiopharmaceutical administered for imaging, up to 14 mCi intravenous (IV).
Study: NCT02143635
Drug: HDM201
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02143635
Drug: ancillary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01536158
Drug: Oral paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours for 3 days.
Study: NCT01536158
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
Study: NCT03757351
Drug: DNL747
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeating oral dose
Study: NCT03757351
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeating oral dose
Study: NCT00437632
Drug: GSK598809
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK598809 will be available as 5 and 25 mg capsules. Subjects will receive GSK598809 capsules orally with water.
Study: NCT00437632
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive matching placebo capsules to GSK598809 orally with water.
Study: NCT00437632
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine 100 mg will be available as oral solution or tablet and subjects will receive Caffeine 100 mg orally on -1 day. On Day 35 caffeine and GSK598809 will be co-administered.
Study: NCT00463242
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03205891
Drug: TAK228
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting Dose and Schedule of TAK228: 2 mg by mouth, 5 days on and 2 days off per week with repeated weekly cycles. The study doctor will tell participant how often to take the study drug.
Study: NCT00415194
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately 100 mL normal saline administered IV, every 21 days, six 21 day cycles
Study: NCT01297465
Drug: Pergoveris®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pergoveris® (follitropin alfa and lutropin alfa) 300 IU will be administered subcutaneously starting from S6 until recombinant human chorionic gonadotropin (r-hCG) administration day (at least 1 follicles \>= 18 mm). The dose of Pergoveris® was adjusted based upon the participant's ovarian response and according to the site's standard practice.
Study: NCT01297465
Drug: Pergoveris®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pergoveris® (follitropin alfa and lutropin alfa) 300 IU will be administered subcutaneously once daily from S1 until r-hCG administration day (at least 1 follicles \>= 18 mm). The dose of Pergoveris® was adjusted starting from S6 based upon the participant's ovarian response and according to the site's standard practice.
Study: NCT00150891
Drug: azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02397408
Drug: Carbon C 11 Choline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given intravenously (IV) prior to imaging
Study: NCT02397408
Drug: Fluorine F 18 Choline
Normalized name: Fluorine F-18
DrugBank: Fluorine F-18 (DB13134)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given intravenously (IV) prior to imaging
Study: NCT02693418
Drug: Acidform 5 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effect of 5 g vaginally administered Acidform on pH over 7 days
Study: NCT02693418
Drug: Placebo 4 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effect of 4 g of vaginally administered HEC placebo gel on pH over 7 days
Study: NCT02693418
Drug: Acidform 4 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effect of 4 g vaginally administered Acidform on pH over 7 days
Study: NCT04662138
Drug: directly acting antivirals
Normalized name: DIRECT ACTING ANTIVIRALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different regimens given for genotype 4 relapse: Sofosbuvir/velpatasvir/voxilaprevir ±ribavirin; sofosbuvir/velpatasvir ±ribavirin; ombitasvir/paritaprevir/ritonavir+ ribavirin
Study: NCT04049617
Drug: Evixapodlin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally.
Study: NCT02693418
Drug: Acidform 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effect of 3 g vaginally administered Acidform on pH over 7 days
Study: NCT01549106
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending dose up to 6 cohorts; multiple ascending dose up to 4 cohorts; food effect arm
Study: NCT03596892
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
Study: NCT03397771
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo medication provided in a dose titration manner
Study: NCT04062656
Drug: Folic acid (FA)
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 200mg/m² IV over 30 min
Study: NCT00316004
Drug: 7.5% Hypertonic Saline (HS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 ml intravenous bolus administration of 7.5% hypertonic saline administered as a one-time bolus fluid for initial resuscitation to injured patients with suspected severe traumatic brain injury in the out-of-hospital setting.
Study: NCT00316004
Drug: 0.9% Normal Saline (NS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 ml intravenous bolus administration of 0.9% saline administered as a one-time bolus fluid for initial resuscitation to injured patients with suspected severe traumatic brain injury in the out-of-hospital setting.
Study: NCT00049829
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00614393
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT00140426
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of risperidone versus placebo for the treatment of symptoms related to anorexia nervosa.
Study: NCT01760525
Drug: CGM097
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients treated with CGM097
Study: NCT02323516
Drug: Acetylsalicylic acid + loperamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: In case of inefficiency in one month, according to predefined criteria, acetylsalicylic acid will be stopped and replaced by diosmectite.
Study: NCT03527381
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 ppm of exogenous gaseous nitric oxide is supplied directly to the oxygenator in the cardiopulmonary bypass circuit during cardiac surgery.
Study: NCT02325518
Drug: Subject's habitual PGA monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00103818
Drug: Comparator: placebo (unspecified)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of Treatment: 3 months
Study: NCT02740699
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive 20-40 mg once daily
Study: NCT03512860
Drug: E4/DRSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT01877746
Drug: Combination of prednisone and azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * Prednisone for a total of 90 days, with initial dose 1mg/kg/day p.o., given for 12 days and then tapered every 5 days for 5mg/day to the maintenance dose of 0.2mg/kg/day. The daily dose of Prednisone will be rounded to the nearest value divisible by 5.~* Azathioprine for 100 days in total, with dose 1 mg/kg/day. The daily dose of Azathioprine will be rounded to the nearest value divisible by 25.
Study: NCT01877746
Drug: Combination of prednisone and azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * Prednisone for a total of 6 months, with initial dose 1mg/kg/day p.o. given for 4 weeks with a subsequent maintenance dose of 0,33 mg/kg/den. The daily dose of Prednisone will be rounded to the nearest value divisible by 5.~* Azathioprine for 6 months in total, with dose 2mg/kg/day. The daily dose of Azathioprine will be rounded to the nearest value divisible by 25.
Study: NCT03560986
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glass vials with matching placebo.
Study: NCT02554136
Drug: HGP0918
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02554136
Drug: HGP0816
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02554136
Drug: HGP0918 + HGP0816
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02958982
Drug: RP3128
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive single oral dose of RP3128 in SAD, multiple dose in MAD AND POC
Study: NCT02958982
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive single oral dose of RP3128 in SAD, multiple dose in MAD AND POC
Study: NCT00437840
Drug: GSK598809
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK598809 capsules will be available in dose strength of 5 and 25 mg. Subjects will receive single oral dose of GSK598809 n order to achieve the required dose.
Study: NCT00437840
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive single oral dose of matching placebo tablet to GSK598809.
Study: NCT00019786
Drug: isolated perfusion
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02752763
Drug: %40 diluted Autologous serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum that obtained after centrifugation of blood sample
Study: NCT02752763
Drug: Preservative free artificial tears(Tears naturale free, Refresh single dose eye drop)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative free artificial tears is a group naming for drops commonly used for drye disease
Study: NCT02166814
Drug: Fimasartan and Rosuvastatin
Normalized name: rosuvastatin and ezetimibe
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02166814
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00751907
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo daily for 4 months
Study: NCT03250494
Drug: combined Dulox capsule (60 mg) orally and Dex 0.1mg/kg diluted in 100 ml 0.9% NS IVI
Approvals — FDA: no, EMA: no, PMDA: no
Description: each patient received combined Dulox capsule (60 mg) orally with sips of water and Dex 0.1mg/kg diluted in 100 ml 0.9% NS IVI over 15 min, 2 hours preoperatively
Study: NCT02803229
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matched placebo provided for placebo arm
Study: NCT00415844
Drug: ELC200 (carbidopa+levodopa+entacapone)
Normalized name: carbidopa / entacapone / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01684163
Drug: GLYX-13 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 10 mg/kg into arm.
Study: NCT02099695
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The quantity of tablets will increase due to the absence/ lack of therapeutic response.
Study: NCT00777413
Drug: Minocycline 100mg Tablets
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01881113
Drug: AC-170 0.24%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop in each eye at 2 separate times during a 14 day period
Study: NCT01881113
Drug: AC-170 0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop in each eye at 2 separate times during a 14 day period
Study: NCT00673387
Drug: placebo-P
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection, twice a day
Study: NCT00673387
Drug: placebo-M
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection, twice a day
Study: NCT00786994
Drug: Placebo (petroleum jelly)
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical use once or twice daily
Study: NCT00004089
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05027243
Drug: Xeomin® (Merz)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For tenderness grade 2, 155U of Incobotulinum toxin A was injected in the masticatory muscles and for tenderness grade 3 195U of Incobotulinum toxin A was injected. The authors used Xeomin® (Merz) in all patients.
Study: NCT01080443
Drug: Mycophenolate Mofetil Capsule 250 mg
Normalized name: mycophenolate mofetil Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
Study: NCT00969631
Drug: metformin HCl (Cidophage®; CID,Cairo, Egypt), CC (Clomid®; Global Napi Pharmaceuticals,Cairo, Egypt),Cairo, Egypt)
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin HCl 1500 daily for 6-8 weeks then 100 mg CC for 5 days starting from day 3 of menstruation up to 6 cycles.
Study: NCT00039520
Drug: sulindac
Normalized name: Sulindac
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04223531
Drug: Normal Saline 0.9% Infusion Solution Bag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a normal saline infusion at a rate of 10ml per unit of body surface area per minute for 120 minutes.
Study: NCT00739986
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo IV x 3 days
Study: NCT03802955
Drug: ADG106
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion over 60 minutes on Day 1 of each cycle, at 7 doses depending on cohort at enrollment.
Study: NCT03542955
Drug: Etoricoxib 60 mg
Normalized name: etoricoxib 60 MG
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: nonsteroidal anti-inflammatory drug used as standard therapy
Study: NCT00804713
Drug: BST
Normalized name: Labstix
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mcg/mL (1 dose) Battey skin test (BST) antigen administered using the Mantoux method.
Study: NCT00804713
Drug: TST
Normalized name: OATSTRAW
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer TB Skin test (TST)
Study: NCT02935205
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03589950
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
Study: NCT03456154
Drug: Botox Injectable Product
Normalized name: Botox Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60u will be used at 3 sites of masseter muscle, on each side of the face
Study: NCT02456558
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In both cohorts, the subjects who were randomized to get placebo will receive an infusion of placebo solution that is equal in volume to that of the active product.
Study: NCT02799368
Drug: CJ Plasma Solution A Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous plasma solution (Chloride 90 mmoL/L) at 3 mL/kg over 1 hour pre-contrast, followed by the same solution intravenously at 1.5 mL/kg/hr for 4 hours. Intra-vascular low-osmolal or iso-osmolal contrast will be used.
Study: NCT02799368
Drug: CJ 0.9% Normal Saline Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous plasma solution (Chloride 154 mmoL/L) at 3 mL/kg over 1 hour pre-contrast, followed by the same solution intravenously at 1.5 mL/kg/hr for 4 hours. Intra-vascular low-osmolal or iso-osmolal contrast will be used.
Study: NCT03598868
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation : Placebo for week 1,2,4,6
Study: NCT00784875
Drug: LY2624803
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg, oral capsule, once nightly before bedtime
Study: NCT00784875
Drug: LY2624803
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg, oral capsule, once nightly before bedtime
Study: NCT00784875
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo (capsule or tablet), once nightly before bedtime
Study: NCT03008876
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: infants receive acetaminophen for treatment of their PDA
Study: NCT03008876
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: infants receive ibuprofen, standard of care in our unit, for treatment of a PDA
Study: NCT02629354
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02629354
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00719849
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg/Kg Day -6
Study: NCT03188666
Drug: REGN2477
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: liquid product for injection/infusion; Route of administration: Intravenous (IV); Administered during treatment periods 1 and 2.
Study: NCT03188666
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Liquid product for injection/infusion; Route of administration: Intravenous (IV); Administered during treatment period 1 only.
Study: NCT00002639
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01529346
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 X 200 mg tablets of ibuprofen administered orally once to the subject on Day 1 postoperatively
Study: NCT04353765
Drug: All authorized TKI monotherapies in advanced RCC per FDA label in advanced RCC
Approvals — FDA: no, EMA: no, PMDA: no
Description: As per authorized FDA label in advanced RCC
Study: NCT02789397
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV placebo will be administered on the same schedule as Rituximab and oral placebo will be administered by mouth daily for 18 months.
Study: NCT01375153
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl administered as a continuous intravenous infusion during four hours
Study: NCT01951885
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX 15mg/m2 IV on day +1, followed by 10mg/m2 on day +3, +6, +11. If patient \< 10 kg then MTX will be given at 0.5 mg/kg IV on day +1. Then MTX will be given at 0.33 mg/kg on days +3, +6 and +11.
Study: NCT01951885
Drug: Methotrexate (low dose)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX 5mg/m2 IV on day +1, +3, +6. If patient\<10 kg MTX will be given at 0.17 mg/kg on day +1, +3, and +6.
Study: NCT02560766
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily
Study: NCT01878461
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01878461
Drug: M518101
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03990597
Drug: Wound Dressing Material
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied StrataXRT topically
Study: NCT02885597
Drug: Juanbi pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4g, twice a day, 3month, oral
Study: NCT02885597
Drug: Juanbi pill placebo
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4g, twice a day, 3month, oral
Study: NCT02885597
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5mg, once a week, 3 month, oral
Study: NCT00496353
Drug: MK2461
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK2461 treatment, bid, 28-day
Study: NCT00440024
Drug: Dove Mild Cleanser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra mild cleanser: Dove Non-foaming cleansing lotion
Study: NCT01687478
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered Orally